Filing Details
- Accession Number:
- 0001209191-12-025352
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-05-02 12:13:01
- Reporting Period:
- 2012-05-01
- Filing Date:
- 2012-05-02
- Accepted Time:
- 2012-05-02 12:13:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 872589 | Regeneron Pharmaceuticals Inc | REGN | Pharmaceutical Preparations (2834) | 133444607 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1218629 | S Leonard Schleifer | 777 Old Saw Mill River Road Tarrytown NY 10591 | President & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2012-05-01 | 2,300 | $133.86 | 384,028 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2012-05-01 | 58,494 | $134.55 | 325,534 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2012-05-01 | 39,106 | $135.29 | 286,428 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2012-05-01 | 100 | $136.57 | 286,328 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 84,773 | Indirect | by GRAT |
| Common Stock | 5,560 | Indirect | by 401(k) Plan |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Class A Stock | $0.00 | 1,710,790 | 1,710,790 | Direct | ||
| Common Stock | Class A Stock | $0.00 | 22,275 | 22,275 | Indirect |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 1,710,790 | 1,710,790 | Direct | |
| 22,275 | 22,275 | Indirect |
Footnotes
- Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 2,300 shares of Company stock on May 1, 2012 at prices ranging from $133.83 to $133.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2012 at each separate price.
- Represents volume-weighted average price of sales of 58,494 shares of Company stock on May 1, 2012 at prices ranging from $134.01 to $134.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2012 at each separate price.
- Represents volume-weighted average price of sales of 39,106 shares of Company stock on May 1, 2012 at prices ranging from $135.00 to $135.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 1, 2012 at each separate price.
- Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.
- Class A Stock of Regeneron Pharmaceuticals, Inc. ("Regeneron") converts to Common Stock of Regeneron on a one-to-one basis upon certain events.
Billionaire Hedge Funds
